Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487

Radionuclide treatment of neuroendocrine tumours with the novel radiolabelled analogue Y-90-SMT 487

Detalhes bibliográficos
Main Authors:	Carroll, P, Maher, K, Foley, R, Stewart, P, Bevan, J, Franklyn, J, Besser, G, Monson, J, Britton, K, Grossman, AB
Formato:	Journal article
Publicado em:	2003

Registos relacionados

Imaging neuroendocrine tumours with radiolabelled somatostatin analogues and X-ray computed tomography: a comparative study.
Por: King, C, et al.
Publicado em: (1993)

Localization of neuroendocrine tumours and insulinomas using radiolabelled somatostatin analogues, 123I-Tyr3-octreotide and 111In-pentatreotide.
Por: Ur, E, et al.
Publicado em: (1993)

Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.
Por: Kaltsas, G, et al.
Publicado em: (2005)

Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.
Por: Kaltsas, G, et al.
Publicado em: (2001)

The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.
Por: Kaltsas, G, et al.
Publicado em: (2001)

Advances in Radionuclides and Radiolabelled Peptides for Cancer Therapeutics
Por: Kushal Chakraborty, et al.
Publicado em: (2023-03-01)

Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.
Por: Kaltsas, G, et al.
Publicado em: (1998)

The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging.
Por: Johnston, L, et al.
Publicado em: (1996)

Targeted radionuclide therapy for neuroendocrine tumours: principles and application.
Por: Druce, MR, et al.
Publicado em: (2010)

MRI of pancreatic neuroendocrine tumours.
Por: Owen, N, et al.
Publicado em: (2001)

Radiolabeling Technique of Silver Nanoparticles (AgNPs) with Iodine-131 Radionuclide
Por: U.N. Sholikhah, et al.
Publicado em: (2020-08-01)

Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours.
Por: Kaltsas, G, et al.
Publicado em: (2004)

Radionuclide imaging of neuroendocrine tumors
Por: Šaponjski Jelena, et al.
Publicado em: (2020-01-01)

Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration.
Por: Jenkins, P, et al.
Publicado em: (2000)

Modular strategic SMT solving with SMT-RAT
Por: Kremer Gereon, et al.
Publicado em: (2018-08-01)

The role of somatostatin analogues in the treatment of neuroendocrine tumours.
Por: Grozinsky-Glasberg, S, et al.
Publicado em: (2008)

Radiolabeled Dendrimer Coated Nanoparticles for Radionuclide Imaging and Therapy: A Systematic Review
Por: Miriam Conte, et al.
Publicado em: (2023-03-01)

RADIONUCLIDE IMAGING AND THERAPY OF NEUROENDOCRINE TUMOURS
Por: Shaunak Navalkissoor, et al.
Publicado em: (2015-11-01)

Pituitary imaging using a labelled somatostatin analogue in acromegaly.
Por: Ur, E, et al.
Publicado em: (1992)

Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms.
Por: Grozinsky-Glasberg, S, et al.
Publicado em: (2008)

Familial paraganglioma: a novel presentation of a case and response to therapy with radiolabelled MIBG.
Por: Lawrence, J, et al.
Publicado em: (2004)

Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.
Por: Kaltsas, G, et al.
Publicado em: (2002)

Ytrium 90 as a radionuclide for therapy
Por: Alejandro Alberti Ramírez
Publicado em: (2012-07-01)

487 Abstract withdrawn
Publicado em: (2023-11-01)

Radionuclide imaging and therapy in patients with neuroendocrine tumors
Por: Olga D. Baranova, et al.
Publicado em: (2018-03-01)

The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.
Por: Siddiqi, A, et al.
Publicado em: (2001)

Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours
Por: Marianne S. Elston, et al.
Publicado em: (2021-12-01)

Neuroendocrine Tumours : From Radiomolecular Imaging to Radionuclide Therapy
Por: GEORGIOS eLIMOURIS
Publicado em: (2012-02-01)

The diagnosis and medical management of advanced neuroendocrine tumors.
Por: Kaltsas, G, et al.
Publicado em: (2004)

The development, commercialization, and clinical context of yttrium-90 radiolabeled resin and glass microspheres
Por: Mark A. Westcott, MD, et al.
Publicado em: (2016-10-01)

Physiologically Based Pharmacokinetic (PBPK) model for biodistribution of radiolabeled peptides in patients with neuroendocrine tumours
Por: Viktor Popov, et al.
Publicado em: (2016-07-01)

Successful neoadjuvant peptide receptor radionuclide therapy for an inoperable pancreatic neuroendocrine tumour
Por: Tiago Nunes da Silva, et al.
Publicado em: (2018-04-01)

Expression of the growth hormone secretagogue receptor in pituitary adenomas and other neuroendocrine tumors.
Por: Korbonits, M, et al.
Publicado em: (1998)

Evaluation of carrier added (CA) and no carrier added (NCA) 177Lu radionuclide roles in radiolabeling of peptide groups
Por: S. Vosoughi, et al.
Publicado em: (2020-11-01)

Peptide receptor radionuclide therapy of neuroendocrine tumors: Case series
Por: Matović Milovan
Publicado em: (2012-01-01)

I-123 imaging for the prediction of I-131 therapy for recurrent differentiated thyroid cancer, RDTC, when I-131 tracer is negative but raised thyroglobulin, Tg
Por: Britton, K, et al.
Publicado em: (1999)

Spinal cord compression after radiolabeled metaiodobenzylguanidine analogue therapy in advanced malignant insulinoma
Por: Alina Coutinho Rodrigues Feitosa, et al.

The traceless Staudinger ligation for indirect 18F-radiolabelling.
Por: Carroll, L, et al.
Publicado em: (2011)

487 peserta sertai Webinar Antarabangsa
Por: Isa, Siti Suriawati, et al.
Publicado em: (2020)

Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI.
Por: Rockall, A, et al.
Publicado em: (2009)